Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
41.11
+0.39 (0.96%)
At close: Oct 15, 2026, 4:00 PM EDT
41.13
+0.02 (0.05%)
After-hours: Oct 15, 2026, 7:49 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Teva Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $47.58. The average 1-year stock price forecast is 15.74% higher than the current stock price, while the lowest is $42 (+2.16%) and the highest is $55 (+33.79%).
Price Target: $47.58 (+15.74%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $42 | Buy | Maintains | $42 | +2.16% | Oct 13, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $47 | Buy | Maintains | $47 | +14.33% | Oct 13, 2026 |
| Leader Capital Markets | Leader Capital Markets | Buy Maintains $50 | Buy | Maintains | $50 | +20.54% | Oct 13, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $50 | Buy | Maintains | $50 | +21.62% | Oct 12, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $40 → $50 | Buy | Maintains | $40 → $50 | +21.62% | Oct 11, 2026 |
Financial Forecast
Revenue This Year
16.66B
from 17.26B
Decreased by -3.49%
Revenue Next Year
17.22B
from 16.66B
Increased by 3.39%
EPS This Year
2.11
EPS Next Year
3.08
from 2.11
Increased by 46.42%
EPS and Forward PE are based on non-GAAP adjusted numbers.